Clinical Trial Update: Study of Pembrolizumab Following TACE in Primary Liver Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating pembrolizumab following transarterial chemoembolization in hepatocellular carcinoma to assess safety and initial efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Imperial College London | Conditions: Primary Liver Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-03